



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2019

Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2019

Publication ID:

GMD0319010

Publication Date:

March 18, 2019

Pages:

105

Publisher:

Global Markets Direct

Region:

Global [1]

\$2,000.00

Publication License Type *

Single User License (PDF), \$2,000.00

Site License (PDF), \$4,000.00

Global License (PDF), \$6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2019, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. PWS is due to lack of several genes on one of an individual's two chromosome 15's. In the majority of cases, there is a deletion. In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15's from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 5, 4, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:

Table of Contents

Introduction

Prader-Willi Syndrome (PWS) - Overview

Prader-Willi Syndrome (PWS) - Therapeutics Development
Prader-Willi Syndrome (PWS) - Therapeutics Assessment
Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
Prader-Willi Syndrome (PWS) - Drug Profiles
Prader-Willi Syndrome (PWS) - Dormant Projects
Prader-Willi Syndrome (PWS) - Discontinued Products
Prader-Willi Syndrome (PWS) - Product Development Milestones
Appendix

List of Tables

List of Tables

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Auris Medical Holding AG, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by ConSynance Therapeutics Inc, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Helsinn Group, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Insys Therapeutics Inc, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Inversago Pharma Inc, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by LG Chem Ltd, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Millendo Therapeutics Inc, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by OptiNose US Inc, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals Inc, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, H1 2019
Prader-Willi Syndrome (PWS) - Pipeline by Zafgen Inc, H1 2019
Prader-Willi Syndrome (PWS) - Dormant Projects, H1 2019
Prader-Willi Syndrome (PWS) - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2019

Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Companies Mentioned:

Auris Medical Holding AG
Chong Kun Dang Pharmaceutical Corp
ConSynance Therapeutics Inc
Ferring International Center SA
Helsinn Group
Insys Therapeutics Inc
Inversago Pharma Inc
LG Chem Ltd
Millendo Therapeutics Inc
OptiNose US Inc
Rhythm Pharmaceuticals Inc
Saniona AB
Soleno Therapeutics Inc
Zafgen Inc

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

[What is drug pipeline research?](#)

March 20

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

Source URL: <https://www.drugpipeline.net/global-markets-direct/prader-willi-syndrome-pws-pipeline-review-h1-2019>

Links

[1] <https://www.drugpipeline.net/region/global>